Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors
©2023 The Authors; Published by the American Association for Cancer Research..
PURPOSE: We explored the clinical and genomic characteristics of hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on cyclin-dependent kinase 4 and 6 inhibitors (CDK4 and 6i) ± endocrine therapy (ET) to understand potential resistance mechanisms that may aid in identifying treatment options.
EXPERIMENTAL DESIGN: Patients in the United States with HR+, HER2- MBC had tumor biopsies collected from a metastatic site during routine care following progression on a CDK4 and 6i ± ET (CohortPost) or prior to initiating CDK4 and 6i treatment (CohortPre) and analyzed using a targeted mutation panel and RNA-sequencing. Clinical and genomic characteristics were described.
RESULTS: The mean age at MBC diagnosis was 59 years in CohortPre (n = 133) and 56 years in CohortPost (n = 223); 14% and 45% of patients had prior chemotherapy/ET, and 35% and 26% had de novo stage IV MBC, respectively. The most common biopsy site was liver (CohortPre, 23%; CohortPost, 56%). CohortPost had significantly higher tumor mutational burden (TMB; median 3.16 vs. 1.67 Mut/Mb, P < 0.0001), ESR1 alteration frequency (mutations: 37% vs. 10%, FDR < 0.0001; fusions: 9% vs. 2%, P = 0.0176), and higher copy-number amplification of genes on chr12q15, including MDM2, FRS2, and YEATS4 versus patients in the CohortPre group. In addition, CDK4 copy-number gain on chr12q13 was significantly higher in CohortPost versus CohortPre (27% vs. 11%, P = 0.0005).
CONCLUSIONS: Distinct mechanisms potentially associated with resistance to CDK4 and 6i ± ET, including alterations in ESR1 and amplification of chr12q15 and CDK4 copy-number gain, were identified.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
Clinical cancer research : an official journal of the American Association for Cancer Research - 29(2023), 17 vom: 01. Sept., Seite 3372-3383 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Rao, Xi [VerfasserIn] |
---|
Links: |
---|
Themen: |
Cyclin-Dependent Kinase 4 |
---|
Anmerkungen: |
Date Completed 04.09.2023 Date Revised 06.09.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1158/1078-0432.CCR-22-3843 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM357910141 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM357910141 | ||
003 | DE-627 | ||
005 | 20231226073616.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1158/1078-0432.CCR-22-3843 |2 doi | |
028 | 5 | 2 | |a pubmed24n1192.xml |
035 | |a (DE-627)NLM357910141 | ||
035 | |a (NLM)37289194 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Rao, Xi |e verfasserin |4 aut | |
245 | 1 | 0 | |a Clinical and Genomic Characteristics of Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 04.09.2023 | ||
500 | |a Date Revised 06.09.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a ©2023 The Authors; Published by the American Association for Cancer Research. | ||
520 | |a PURPOSE: We explored the clinical and genomic characteristics of hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on cyclin-dependent kinase 4 and 6 inhibitors (CDK4 and 6i) ± endocrine therapy (ET) to understand potential resistance mechanisms that may aid in identifying treatment options | ||
520 | |a EXPERIMENTAL DESIGN: Patients in the United States with HR+, HER2- MBC had tumor biopsies collected from a metastatic site during routine care following progression on a CDK4 and 6i ± ET (CohortPost) or prior to initiating CDK4 and 6i treatment (CohortPre) and analyzed using a targeted mutation panel and RNA-sequencing. Clinical and genomic characteristics were described | ||
520 | |a RESULTS: The mean age at MBC diagnosis was 59 years in CohortPre (n = 133) and 56 years in CohortPost (n = 223); 14% and 45% of patients had prior chemotherapy/ET, and 35% and 26% had de novo stage IV MBC, respectively. The most common biopsy site was liver (CohortPre, 23%; CohortPost, 56%). CohortPost had significantly higher tumor mutational burden (TMB; median 3.16 vs. 1.67 Mut/Mb, P < 0.0001), ESR1 alteration frequency (mutations: 37% vs. 10%, FDR < 0.0001; fusions: 9% vs. 2%, P = 0.0176), and higher copy-number amplification of genes on chr12q15, including MDM2, FRS2, and YEATS4 versus patients in the CohortPre group. In addition, CDK4 copy-number gain on chr12q13 was significantly higher in CohortPost versus CohortPre (27% vs. 11%, P = 0.0005) | ||
520 | |a CONCLUSIONS: Distinct mechanisms potentially associated with resistance to CDK4 and 6i ± ET, including alterations in ESR1 and amplification of chr12q15 and CDK4 copy-number gain, were identified | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 7 | |a Cyclin-Dependent Kinase 4 |2 NLM | |
650 | 7 | |a EC 2.7.11.22 |2 NLM | |
650 | 7 | |a ERBB2 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.10.1 |2 NLM | |
700 | 1 | |a Chen, Yongmei |e verfasserin |4 aut | |
700 | 1 | |a Beyrer, Julie |e verfasserin |4 aut | |
700 | 1 | |a Nash Smyth, Emily |e verfasserin |4 aut | |
700 | 1 | |a Morato Guimaraes, Claudia |e verfasserin |4 aut | |
700 | 1 | |a Litchfield, Lacey M |e verfasserin |4 aut | |
700 | 1 | |a Bowman, Lee |e verfasserin |4 aut | |
700 | 1 | |a Lawrence, Garreth W |e verfasserin |4 aut | |
700 | 1 | |a Aggarwal, Amit |e verfasserin |4 aut | |
700 | 1 | |a Andre, Fabrice |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Clinical cancer research : an official journal of the American Association for Cancer Research |d 1995 |g 29(2023), 17 vom: 01. Sept., Seite 3372-3383 |w (DE-627)NLM09444479X |x 1557-3265 |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:2023 |g number:17 |g day:01 |g month:09 |g pages:3372-3383 |
856 | 4 | 0 | |u http://dx.doi.org/10.1158/1078-0432.CCR-22-3843 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 29 |j 2023 |e 17 |b 01 |c 09 |h 3372-3383 |